Treatments · Entity Annotation Prototype (beta)

1articles mentioning treatments

4treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: OUTLAST™ conditioning ×

OUTLAST™ conditioning

This treatment is selected. Its supporting articles are shown below.

OUTLAST™ conditioning1

Articles mentioning OUTLAST™ conditioning

1 articles · page 1 of 1

545 A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IB-T101, an OUTLAST™-conditioned CD70-targeted CAR-T cell therapy, in patients with clear cell renal cell carcinoma

jitc · abstract · 2025-11-04 · 4 matching annotations

84.9%

OUTLAST™ conditioning IB-T101 ccRCC hematologic malignancies Tongji Hospital Medical Ethics Committee ID TJ-IRB202412051-1

… an autologous CAR-T targeting CD70 in ccRCC, is expanded under OUTLAST™ conditioning to address the challenges of the solid tumor TME. OUTLAST™ cond…

Browse treatments

OUTLAST™ conditioning

Articles mentioning OUTLAST™ conditioning

545 A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IB-T101, an OUTLAST™-conditioned CD70-targeted CAR-T cell therapy, in patients with clear cell renal cell carcinoma